Pulmonary Arterial Hypertension: Classification, Diagnosis and Contemporary Management

Overview

Journal Postgrad Med J

Publisher Oxford University Press

Specialty General Medicine

Date 2006 Nov 14

PMID 17099090

Citations 2

Authors

D J Fox

R S Khattar

Affiliations

Soon will be listed here.

Citing Articles

Patient-specific finite element analysis of heart failure and the impact of surgical intervention in pulmonary hypertension secondary to mitral valve disease.

Heidari A, Elkhodary K, Pop C, Badran M, Vali H, Abdel-Raouf Y Med Biol Eng Comput. 2022; 60(6):1723-1744.

PMID: 35442004 DOI: 10.1007/s11517-022-02556-6.

Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.

Pankey E, Epps M, Nossaman B, Hyman A, Kadowitz P J Clin Rheumatol Musculoskelet Med. 2013; 1(2):11-20.

PMID: 23626904 PMC: 3636503.

References

Kerstein D, LEVY P, Hsu D, Hordof A, Gersony W, Barst R . Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation. 1995; 91(7):2028-35. DOI: 10.1161/01.cir.91.7.2028. View

Farber H, Loscalzo J . Pulmonary arterial hypertension. N Engl J Med. 2004; 351(16):1655-65. DOI: 10.1056/NEJMra035488. View

Sandoval J, Gaspar J, Pulido T, Bautista E, Zeballos M, Palomar A . Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol. 1998; 32(2):297-304. DOI: 10.1016/s0735-1097(98)00238-1. View

Doyle R, McCrory D, Channick R, Simonneau G, Conte J . Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126(1 Suppl):63S-71S. DOI: 10.1378/chest.126.1_suppl.63S. View

Fishman A, Moser K, Fedullo P . Perfusion lung scans vs pulmonary angiography in evaluation of suspected primary pulmonary hypertension. Chest. 1983; 84(6):679-83. DOI: 10.1378/chest.84.6.679. View

Rubin L . Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126(1 Suppl):4S-6S. DOI: 10.1378/chest.126.1_suppl.4S. View

Barst R, Rich S, Widlitz A, Horn E, McLaughlin V, McFarlin J . Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest. 2002; 121(6):1860-8. DOI: 10.1378/chest.121.6.1860. View

Rubin L, Badesch D, Barst R, Galie N, Black C, Keogh A . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346(12):896-903. DOI: 10.1056/NEJMoa012212. View

de Chadarevian J, LISCHNER H, Karmazin N, Pawel B, Schultz T . Pulmonary hypertension and HIV infection: new observations and review of the syndrome. Mod Pathol. 1994; 7(6):685-9. View

10.

Kim H, Yung G, Marsh J, Konopka R, Pedersen C, Chiles P . Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J. 2000; 15(4):640-8. DOI: 10.1034/j.1399-3003.2000.15d04.x. View

11.

Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R . Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest. 2003; 123(4):1293-5. DOI: 10.1378/chest.123.4.1293. View

12.

Simonneau G, Barst R, Galie N, Naeije R, Rich S, Bourge R . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165(6):800-4. DOI: 10.1164/ajrccm.165.6.2106079. View

13.

Gaine S, Rubin L . Primary pulmonary hypertension. Lancet. 1998; 352(9129):719-25. DOI: 10.1016/S0140-6736(98)02111-4. View

14.

Giaid A, Yanagisawa M, Langleben D, Michel R, Levy R, Shennib H . Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328(24):1732-9. DOI: 10.1056/NEJM199306173282402. View

15.

. International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society(ATS)/European Respiratory Society(ERS)/International Society for Heart and Lung.... Am J Respir Crit Care Med. 1998; 158(1):335-9. DOI: 10.1164/ajrccm.158.1.15812. View

16.

McLaughlin V, Shillington A, Rich S . Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106(12):1477-82. DOI: 10.1161/01.cir.0000029100.82385.58. View

17.

McMahon T, Ignarro L, Kadowitz P . Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J Appl Physiol (1985). 1993; 74(4):1704-11. DOI: 10.1152/jappl.1993.74.4.1704. View

18.

Barst R, Rubin L, Long W, McGoon M, Rich S, Badesch D . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334(5):296-301. DOI: 10.1056/NEJM199602013340504. View

19.

Lane K, Machado R, Pauciulo M, Thomson J, Phillips 3rd J, Loyd J . Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000; 26(1):81-4. DOI: 10.1038/79226. View

20.

DAlonzo G, Barst R, Ayres S, Bergofsky E, Brundage B, Detre K . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115(5):343-9. DOI: 10.7326/0003-4819-115-5-343. View